ALNY Q1 2018 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+15.5% YoY

Gross Profit

$22M100.0% margin

Operating Income

-$147M-673.1% margin

Net Income

-$141M-644.8% margin

EPS (Diluted)

$-1.41

QoQ Revenue Growth

-42.3%

Cash Flow

Operating Cash Flow

-$156M

Free Cash Flow

-$177M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$168M

Stockholders' Equity

$1.8B

Cash & Equivalents

$396M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$19M	+15.5%
Gross Profit	$22M	$19M	+15.5%
Operating Income	-$147M	-$107M	-38.4%
Net Income	-$141M	-$107M	-31.6%